This effort supports employees by enhancing their strengths and addressing any development gaps through individual and group coaching and sponsorship. You can unsubscribe from these emails at any time. www.vaers.hhs.gov to file a report, or call JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. ORAL PRESENTATION: Kohli A, et al. Future Leaders graduate programme The Patient Journey in Patients with CRSwNP in the United States and Europe. Reasons why patients with severe asthma discontinue biologic treatment, Impact of mepolizumab in patients with life-threatening asthma, CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy, Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys, CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial, Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting ?2-agonist, Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation, Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population, Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation, Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial, Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial, Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model, Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components, Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians, Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD), Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population, Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs, Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network, Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018, Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Bogart M, Germain G, Lalibert F, et al. 1. GSK is an Equal Opportunity/Affirmative Action Employer. Sort by: relevance - date. Poster No. 3. The PI3K/AKT and phosphatase and tensin homolog (PTEN) pathways are among the most frequently mutated pathways in human cancers. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de 6. 1. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. Eur J Cancer. Schwarz TF et al. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Poster No. Ismaila A, Czira A, Haeussler K, et al. Singh AK, et al. 2. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) 2. MyOldMeds.com/blogrV. Cancer Discov. P0017. Tim-3 and its role in regulating anti-tumor immunity. 1. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Nat Med. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. ORAL PRESENTATION: Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY), 1. 804; Abstract A7741]. J Clin Invest. Zhang S, Czira A, Harley J, et al. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. P1286; Abstract A6579]. 4. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. You will now be taken from the GSK U.S. Medical POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. real person. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. 2017;35(15):suppl TPS3113. P787; Abstract A5625]. GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Hellmich B, Neukirch K, Lukas M, et al. Gupte R, Liu Z, Kraus WL. Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates, 2. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 9. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. Bogart M, Han X, Bengtson L, et al. 2017;31(2):101-1261. 2004;199(1):91-98. Bogart M, Han X, Bengtson L, et al. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. Slade D, Ray R, Moretz C, et al. Najafov A, Chen H, Yuan J. Necroptosis and cancer. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. GSK Global Medical Affairs Lead Jobs | Glassdoor Bell CF, Blauer-Peterson C. Further details on cookies and how to object to their placement can be found in our Cookie Policy. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgren?s Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. The information you are about to be referred to may not comply with the local regulatory requirements. Cho E-Y, Lee E-B, Yang S-H, et al. 2. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis? Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 2017;47(5):765-779. 373. POSTER: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real world single center experience (Presentation Is Not Available Due to Copyright), 7. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. 2015;21(8):914-921. P1505. P1045; Abstract A5050]. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. We also share information about your use of our site with our advertising, social media and analytics partners. Learn more: gsk.to/3KRNW1B. 2. Corbridge T, Deb A, Germain G, et al. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. POSTER: ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) Dostarlimab Followed by Niraparib Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC, 2. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Seifert L, Werba G, Tiwari S, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. excuses voor het ongemak. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? 2. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-cell?dependent tumor immunity. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. 1. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). P1501. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Lu E, Mu G, Alfonso-Cristancho R. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. message, please email 1. Click to select your career area and upload your resume. Areas, Search Medical Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. PO2409, 3. Our market sites can be reached by visiting our location selector. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. 373. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. The recruitment process is key to starting off on the right foot. 347). Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis, 6. 1. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. 2015;23:82-91. Dostarlimab is a humanized anti?PD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. P1483. GSK Mularski RA, Drummond MB, Jain R, et al. McCormack E, Adams KJ, Hassan NJ, et al. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis ?of REALITI-A? Silver J, Bogart M, Molfino N, et al. Immunotherapy. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. 3. Review the package insert for important safety information. 22 Gsk Medical Affairs jobs in London, England, United Kingdom (2 new) Today's top 22 Gsk Medical Affairs jobs in London, England, United Kingdom. 1. 2. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore), 2. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. We use cookies to personalise content and ads, to provide social media features and to analyse our websites. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. P372; Abstract A6482]. 178 Medical Affairs Jobs in London, England, United Kingdom (9 new) Regulatory Affairs Officer / RAQA Officer Hays Uxbridge, England, United Kingdom Be an early applicant 4 weeks ago. 2017;31(2):101-126. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. 2. David Brooks - Vice President, Country Medical Director, UK - LinkedIn Use of Mepolizumab among Individuals with Asthma in the U.S. Cancer Immunol Res. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. Consider joining our contingent talent community for contract opportunities. Wu AC, McMahon PM, Mendelsohn A, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. 5. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment? in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Singer D et al. Abstract Publication No. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Ferguson GT, Brown N, Compton C, et al. P824; Abstract A4313]. Slade D, Ray R, Moretz C, et al. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. McCreary G, Yawn BP, Linnell J, et al. Poster No. Registered in England and Wales No. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Targeting B-cell maturation antigen in multiple myeloma. 6. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). 1301; Abstract A1312]. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. We bring together the best and brightest minds to be ambitious for our patients. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Search job openings, see if they fit - company salaries, reviews, and more posted by GSK employees.
Valdosta State Football Coaches,
La Mujer Pecadora Y El Frasco De Alabastro,
Apple Consumer Law Usa,
Hamilton County Board Of Elections Jobs,
Articles G